A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelofibrosis
- Focus Therapeutic Use
- 02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 06 Jan 2009 Planned end date changed from 1 Aug 2008 to 1 Aug 2009 as reported by ClinicalTrials.gov.